The role of comorbidity in the management and prognosis in nonsmall cell lung cancer: a population-based study
Open Access
- 9 May 2017
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 56 (7), 949-956
- https://doi.org/10.1080/0284186x.2017.1324213
Abstract
Background: Coexisting disease constitutes a challenge for the provision of optimal cancer care. The influence of comorbidity on lung cancer management and prognosis remains incompletely understood. We assessed the influence of comorbidity on treatment intensity and prognosis in a population-based setting in patients with nonsmall cell lung cancer. Material and methods: Our study was based on information available in Lung Cancer Data Base Sweden (LcBaSe), a database generated by record linkage between the National Lung Cancer Register (NLCR) and several other population-based registers in Sweden. The NLCR includes data on clinical characteristics on 95% of all patients with lung cancer in Sweden since 2002. Comorbidity was assessed using the Charlson Comorbidity Index. Logistic regression and time to event analysis was used to address the association between comorbidity and treatment and prognosis. Results: In adjusted analyses encompassing 19,587 patients with a NSCLC diagnosis and WHO Performance Status 0–2 between 2002 and 2011, those with stage-IA–IIB disease and severe comorbidity were less likely to be offered surgery (OR: 0.45; 95% CI: 0.36–0.57). In late-stage disease (IIIB–IV), severe comorbidity was also associated with lower chemotherapy treatment intensity (OR: 0.76; 95% CI: 0.65–0.89). In patients with early, but not late-stage disease, severe comorbidity in adjusted analyses was associated with an increased all-cause mortality, while lung cancer-specific mortality was largely unaffected by comorbidity burden. Conclusions: Comorbidity contributes to the poor prognosis in NSCLC patients. Routinely published lung cancer survival statistics not considering coexisting disease conveys a too pessimistic picture of prognosis. Optimized management of comorbid conditions pre- and post-NSCLC-specific treatment is likely to improve outcomes.Keywords
Funding Information
- Swedish Cancer Society (15-0804)
- Regional Research Council Uppsala-Örebro (RFR-654111)
- Regional Research Council Uppsala-Örebro (RFR-654111)
This publication has 23 references indexed in Scilit:
- Mortality and survival of lung cancer in Denmark: Results from the Danish Lung Cancer Group 2000–2012Acta Oncologica, 2016
- Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysisLung Cancer, 2015
- The direct and indirect impact of comorbidity on the survival of patients with non-small cell lung cancer: a combination of survival, staging and resection models with missing measurements in covariatesBMJ Open, 2014
- The effect of comorbidity on stage-specific survival in resected non-small cell lung cancer patientsEuropean Journal of Cancer, 2012
- Risk model of in-hospital mortality after pulmonary resection for cancer: A national database of the French Society of Thoracic and Cardiovascular Surgery (Epithor)The Journal of Thoracic and Cardiovascular Surgery, 2011
- Epidemiology of Lung Cancer Prognosis: Quantity and Quality of LifeMethods in Molecular Biology, 2009
- Comorbidities and Charlson score in resected stage I nonsmall cell lung cancerEuropean Respiratory Journal, 2005
- Prognostic Importance of Comorbidity in a Hospital-Based Cancer RegistryPublished by American Medical Association (AMA) ,2004
- Impact of comorbidity on survival after surgical resection in patients with stage I non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2002
- Perspectives on Comorbidity and Cancer in Older Patients: Approaches to Expand the Knowledge BaseJournal of Clinical Oncology, 2001